Compare Boston Beer Company Inc (SAM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs TransMedics Group Inc — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: TransMedics Group Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| SAM | TMDX | |
|---|---|---|
Market Cap | $1.88B | $2.54B |
Sector | Consumer Staples | Technology |
52-Week High | $260.05 | $150.42 |
52-Week Low | $161.08 | $61.99 |
Enterprise Value | $1.75B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.98, down 4.37% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, though 2026 projections show potential challenges with expected revenue decline and negative margins. Recent earnings show a mix of beats and misses, with Q2 2026 results pending.
The stock presents a cautious opportunity with analyst consensus target of $204.33 suggesting 19% upside, but faces headwinds from declining volumes, competitive pressure in hard seltzer market, and negative FY26 EPS growth projections. Institutional sentiment leans neutral with 74% hold ratings, reflecting balanced risk-reward amid evolving consumer beverage preferences.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
